title: Chlorpropamide-induced ADH release, hyponatremia and central pontine myelinolysis in diabetes mellitus.
abstract: Chlorpropamide (CPM) has been reported to produce impaired water excretion due to the enhancement of renal vasopressin (ADH) action and/or due to centrally enhanced ADH release, but it is still unknown whether CPM gives rise to ADH release with a subsequent hyponatremia in diabetes mellitus (DM), which, in turn, causes an impairment of the central nervous system. In 3 patients with DM, who developed hyponatremia during the treatment with CPM, an acute water load (WL) was carried out in the presence and absence of the drug, and plasma ADH was determined with plasma and urine osmolalities. Moreover, in 2 cases, MRI scans of the brain were taken. In all the patients, acute WL tests failed to suppress completely ADH release in response to changes in plasma osmolality in the presence of CPM, which, in turn, resulted in the impaired water excretion. In the absence of CPM, an acute WL normally suppressed plasma ADH leading to the diuresis. MRI scans illustrated the presence of central pontine myelinolysis. It is likely that CPM might stimulate ADH release in DM with a subsequent hyponatremia and brain damages.
authors.affiliation: Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai.
authors.forename: T
authors.initials: T
authors.lastname: Kimura
authors.forename: K
authors.initials: K
authors.lastname: Ota
authors.forename: M
authors.initials: M
authors.lastname: Shoji
authors.forename: T
authors.initials: T
authors.lastname: Funyu
authors.forename: M
authors.initials: M
authors.lastname: Ohta
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Yamamoto
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.forename: T
authors.initials: T
authors.lastname: Sahata
authors.forename: K
authors.initials: K
authors.lastname: Sugimura
mesh_terms: D000368:Aged; D002747:Chlorpropamide / Q000009:adverse effects*; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007010:Hyponatremia / Q000139:chemically induced* / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D011149:Pons / Q000378:metabolism* / Q000473:pathology; D014667:Vasopressins / Q000096:biosynthesis* / Q000097:blood / Q000652:urine
chemical_list: D007004:Hypoglycemic Agents; D014667:Vasopressins; D002747:Chlorpropamide